Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
S Bruno,S Bollani,A L Zignego,J M Pascasio,C Magni,A Ciancio,M Caremani,A Mangia,S Marenco,S Piovesan,L Chemello,S Babudieri,A Moretti,F Gea,C Colletta,R Perez-Alvarez,X Forns,J R Larrubia,J Arenas,J Crespo,V Calvaruso,F Ceccherini Silberstein,P Maisonneuve,A Craxì,J L Calleja,Italian and Spanish (IAS)-BoC Study Group,V Di Marco,M Monti,G Rizzardini,S Landonio,M Rizzetto,L E Lapini,V Piazzolla,A Picciotto,A Alberti,L Cavaletto,M Koch,M Massari,L Muratori,V Cipriano,A Montineri,C Iacobello,S Fangazio,M Pirisi,A Colombo,G Bellati,F Mazzotta,P Pierotti,A Traverso,G Serviddio,M Russello,T Santantonio,D Drenaggi,E Marchionne,M Zuin,M Delliponti,F Farina,P Andreone,A Scuteri,M Galli,E G Giannini,A Nerli,S Carbonai,N Coppola,M Montalbano,V Portelli,A Di Biagio,L A Nicolini,C Mastroianni,S Madonia,A Licata,G Montalto,L Giannitrapani,M Mondelli,A Pellicelli,P Toniutto,G Borgia,I Gentile,M De Luca,G G Di Costanzo,G Corti,V Cento,M Sousa,M B Delgado,J De la Revilla,J M Navarro,R Barcena,M Romero-Gomez,C M Fernandez-Rodriguez,I Narvaez,J C Erdozain,E Molina,I Fernandez,B Cuenca,R Planas,J Garcia-Samaniego,J M Ladero,J M Gonzalez,M A Serra,I Castellote,R Sola,T Anton,I Ryan,F Gonzalez,E Martinez,J Portu
DOI: https://doi.org/10.1111/jvh.12342
Abstract:In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10 -decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/μL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.